Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

被引：0
|
作者：
Tobon, Katherine [1 ]
Consalvo, Kylie [2 ]
Kareem, Syeda Saba [1 ]
Lancet, Jeffrey E. [1 ]
Komrokji, Rami S. [1 ]
Pinilla-Ibarz, Javier [3 ]
Sallman, David [1 ]
Eatrides, Jennifer [4 ]
Walker, Alison R. [1 ]
Chavez, Julio C. [1 ]
Isenalumhe, Leidy Lismeris [1 ]
Shah, Bijal [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Community & Satellite Oncol, Tampa, FL USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-201486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2821 / 2821
页数：1
相关论文
共 50 条
  • [21] Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Data from a Nationwide Belgian Registry
    Devos, Timothy
    Havelange, Violaine
    Theunissen, Koen
    Meers, Stef
    Benghiat, Fleur Samantha
    Gadisseur, Alain
    Vanstraelen, Gaetan
    Andre, Marc
    Bailly, Benjamin
    Granacher, Nikki
    Lewalle, Philippe
    De Becker, Ann
    Van Eygen, Koen
    Lejeune, Marie
    Deeren, Dries
    Nifosi, Gianfilippo
    Triffet, Agnes
    Vrelust, Inge
    Bekaert, Julie
    Beck, Michael
    Selleslag, Dominik
    BLOOD, 2019, 134
  • [22] Spotlight on Dasatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    McCormack, Paul L.
    Keam, Susan J.
    BIODRUGS, 2012, 26 (01) : 61 - 64
  • [23] Spotlight on dasatinib in chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
    McCormack P.L.
    Keam S.J.
    BioDrugs, 2012, 26 (1) : 61 - 64
  • [24] Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Tanimura, Kazuki
    Yamasaki, Kai
    Okuhiro, Yuki
    Hira, Kota
    Nitani, Chika
    Okada, Keiko
    Fujisaki, Hiroyuki
    Matsumoto, Kana
    Hara, Junichi
    CASE REPORTS IN ONCOLOGY, 2021, 14 (01): : 24 - 28
  • [25] A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Matloub, Yousif
    Gore, Lia
    Loh, Mignon L.
    Pui, Chin-Hon
    Hanley, Michael J.
    Lu, Vickie
    Leonard, E. Jane
    Granier, Muriel
    Biondi, Andrea
    Silverman, Lewis B.
    BLOOD, 2020, 136
  • [26] A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Nguyen, Daniel
    Jabbour, Elias
    Short, Nicholas
    Issa, Ghayas C.
    Yilmaz, Musa
    Daver, Naval
    Pemmaraju, Naveen
    Chien, Kelly S.
    Masarova, Lucia
    Ravandi, Farhad
    Jain, Nitin
    Deen, Wuliamatu
    Zhao, Min
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 6127 - 6129
  • [27] The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia
    Wu, Xiaoxia
    Lu, Shenqi
    Zhang, Xinhui
    Yang, Zhen
    Sun, Aining
    Wu, Depei
    Zhou, Huifen
    Miao, Miao
    CANCER MEDICINE, 2024, 13 (17):
  • [28] Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge
    Thomas, Deborah A.
    Faderl, Stefan
    Jones, Dan
    Jabbour, Elias
    Koller, Charles
    Dara, Samuel
    Garris, Rebecca
    Kebriaei, Partow
    Borthakur, Gautam
    Ferrajoli, Alessandra
    O'Brien, Susan
    BLOOD, 2009, 114 (22) : 806 - 807
  • [29] Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Treated with Ponatinib in the PACE Trial
    Mauro, Michael J.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Muller, Martin C.
    Gambacorti-Passerini, Carlo
    Wong, Stephane
    Dorer, David J.
    Knickerbocker, Ronald Keith
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Guilhot, Francois
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy
    Goldman, John M.
    Shah, Neil
    Kantarjian, Hagop M.
    BLOOD, 2012, 120 (21)
  • [30] Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL): A phase II study
    Nasr, Lewis Fady
    Jabbour, Elias
    Haddad, Fadi
    Short, Nicholas James
    Macaron, Walid
    Nasnas, Cedric Christophe
    Zoghbi, Marianne
    Issa, Ghayas C.
    Yilmaz, Musa
    Daver, Naval Guastad
    Pemmaraju, Naveen
    Masarova, Lucia
    Ravandi, Farhad
    Jain, Nitin
    Deen, Wuliamatu
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Garris, Rebecca
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345